Nexstim Plc · OMXHEX:NXTMH
Nexstim — FY2023 Earnings Presentation
12 slides from Nexstim's earnings presentation, Feb 27, 2024
Slide 1: Nexstim - Personalized Brain Diagnostics and Therapy
Nexstim - Personalized Brain Diagnostics and Therapy Mikko Karvinen| CEO| Nexstim Plc Joonas Juokslahti| CFO| Nexstim Plc H2 2023 & FY 2023 Financial Results Webinar, 27 February 2024
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Nexstim Story
Nexstim Story Nexstim is a Finnish, globally operating growth-oriented medical technology company. MISSION VISION VALUES • We enable personalized and • With our technological know-how • Science and clinical evidence effective therapies and and superior services, • Financial success diagnostics for c
Slide 4: Megatrends that Support our Growth
Megatrends that Support our Growth Nexstim’s unique proprietary neuronavigated TMS-technology for both diagnostic and therapy applications. 1 2 3 Technological Healthcare cost Aging population development in pressures healthcare • Population aging and a • Technological • The need for more significan
Slide 5: Our Business and Products
Our Business and Products Commercial Business System Application Europe United States Status NBS Diagnostics (Navigated Over 230 Pre-surgical FDA CE marked Business Brain systems sold mapping approved Stimulation) FDA approved NBT® Over 80 Depression CE marked with existing Therapy (Navigated system
Slide 6: Business and Financial Summary H2 2023
Nexstim Business and Financial Summary H2 2023 • The end of 2023 was a record-breaking for Nexstim in • System sales were EUR 3.0M (2022 H2: EUR 1.3M), terms of net sales and operating result with an increase of 127.5%. Recurring net sales were • Continued to focus on projects important to the compa
Slide 7: Financial Progress H2 2020-2023
Nexstim Financial Progress H2 2020-2023 Comparable net sales Comparable GM 5 000 1,2 4 500 1 4 000 +73.5% 3 500 0,8 3 000 EUR 1000 2 500 0,6 2 000 0,4 1 500 1 000 0,2 500 0 0 H2 20 H2 21 H2 22 H2 23 Nexstim Oyj Nexstim Plc Public Presentation 7
Slide 8: H2 & Full Year 2023 Key Financials
H2 & Full Year 2023 Key Financials 7–12/2023 7–12/2022 1–12/2023 1–12/2023 Change-% Net sales 7.2M€ -24% EUR in thousands Change-% 6 months 6 months 12 months 12 months • Comparable 7.2M€ +21% • System Sales 4.1M€ +33% Net Sales 4,742.6 2,733.7 73.5% 7,246.3 9,526.7 -23.9% • Recurring 3.2M€ +8% • Li
Slide 9: Comparable Net Sales & Gross Margins 2020-2023
Comparable Net Sales & Gross Margins 2020-2023 Comparable net sales Comparable GM 8 000 7 000 6 000 5 000 EUR 1000 4 000 3 000 2 000 1 000 0 FY 20 FY 21 FY 22 FY 23 Nexstim Oyj Nexstim Plc Public Presentation 9
Slide 10: Key Strategic Objectives 2024
Nexstim Key Strategic Objectives 2024 1 2 3 Profitable Growth Technology Leadership Strategic Partnerships To increase comparable Launch of the new NBS 6 Expanding Nexstim's net sales and improve diagnostics product, network of partners and operating result for the enabling easy-to-use clinics, prim
Slide 11: NBS 6 – future of the Nexstim system
NBS 6 – future of the Nexstim system Developing and lauching a new product generation is an essential part of Nexstim’s work during the 2020-2024 strategy period • The NBS 6 is a new combined system that has been built 1 on Nexstim’s unique, clinically established technology. • The modular product d
Slide 12: Thank you!
Thank you! @NexstimOyj Follow us on social media: @Nexstim @NexstimTMS Nexstim Oyj Nexstim Plc Public Presentation 12